Grabenstetter, Anne http://orcid.org/0000-0001-8419-6167
Brogi, Edi http://orcid.org/0000-0003-4737-8468
Zhang, Hong
Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
VanZee, Kimberly J. http://orcid.org/0000-0001-9550-4647
Norton, Larry http://orcid.org/0000-0003-3701-9250
Wen, Hannah Y.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748, P30CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 11 April 2022
Accepted: 28 July 2022
First Online: 11 August 2022
Competing interests
: The authors declare the following competing financial interests: A.G. is a consultant for Paige.AI. J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI and Eli Lilly, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics, Paige.AI and Personalis, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. P.R. reports receiving institutional grant/funding from Grail/Illumina, Novartis, AstraZeneca, Epic Sciences, Invitae/ArcherDx, Tempus, Inivata, Biothernostics; and Consultation/Ad board/Honoraria from Novartis, Foundation Medicine, AstraZeneca, Pfizer, Daiichi, Epic Sciences, Inivata, Natera, Biovica, and Tempus. H.Y.W. reports consultancy fees from AstraZeneca. L.N. declares no competing financial interests. L.N. and J.S.R.-F. are Editors-in-chief of npj Breast Cancer. A.G., P.R., and H.Y. Wen declare no competing non-financial interests. E.B., H.Z., and K.J.V.Z. declare no competing financial or non-financial interests.
: IRB approval was not required per Memorial Sloan Kettering institutional policy, and all additional relevant ethical considerations were complied with.